# Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct04938583/  
OnCo record `nct04938583` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Oregovomab, Bevacizumab, Paclitaxel / nab-paclitaxel in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.

## Summary

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer is a phase 1/2 interventional study registered as NCT04938583 by CanariaBio Inc., with 54 participants planned, started 2021-03-17 and due to reach its primary completion in 2025-10-30. Interventions recorded: Oregovomab, Bevacizumab, Paclitaxel, Carboplatin. Conditions listed: Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04938583
- Phase: 1/2
- Setting: Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer
- Sponsor: CanariaBio Inc.
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT04938583: https://clinicaltrials.gov/study/NCT04938583

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Oregovomab](https://onco.cc/drugs/oregovomab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct04938583.json